Following the recent earnings report, the consensus from 22 analysts covering Moderna is for revenues of US$4.26b in 2024. This implies a stressful 38% decline in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 42% to US$7.11. Before this latest report, the consensus had been expecting revenues of US$4.40b and US$6.43 per share in losses. So it's pretty clear the analysts have mixed opinions on Moderna after this update; revenues were downgraded and per-share losses expected to increase.